University of Michigan Medical School
University of Michigan Medical School
Otolaryngology at University of Michigan Hospitals, where he served as Chief Resident
Otolaryngology - Head and Neck Surgery
A highly accomplished physician who has been practicing medicine in Sacramento since 1989, Dr. David Evans is a board-certified otolaryngologist who treats the spectrum of disorders relating to the ear, nose and throat. Dr. Evans specializes in the treatment of adult and pediatric otolaryngology. These include tonsil and adenoid problems, ear problems, sinus and nasal problems, snoring, and sleep apnea. Dr. Evans is an experienced teacher, having made numerous presentations to local physicians on important clinical updates in otolaryngology. He also has participated in extensive clinical research in otolaryngology; some of the results of his research were published in national otolaryngology journals. In addition, Dr. Evans currently serves as Medical Director for Pediatric Otolaryngology at Sutter Children’s Center, Sacramento. He has also served previously as Chairman of the Department of Surgery at Sutter Medical Center Sacramento, and as President of the Sacramento Society of Otolaryngology-Head and Neck Surgery. He donates his time to the Sutter Cleft Palate and Craniofacial Anomalies Panel.
Dr. Evans received his medical degree from University of Michigan Medical School, where he graduated with distinction. He then went on to complete his residency in Otolaryngology at University of Michigan Hospitals, where he served as Chief Resident.
Dr. Evans is a member of the American Academy of Otolaryngology and a Fellow of the American College of Surgeons. He is affiliated with Sutter and Mercy Hospitals in Sacramento.
14/DEC/2006-05/FEB/2008 Accentia Biopharmaceuticals: ACC-05-01 A prospective, randomized, double bind, placebo-controlled, multicenter, parallel-group study of intranasal XXXXXX in patients with refractory, postsurgical chronic sinusitis (CS)
19/APR/2007-17/JAN/2008 Alcon: C-05-35 Safety and Efficacy of XXXXX in the Treatment of Acute Otitis Media with Otorrhea Through Tympanostomy Tubes (AOMT)
20/JUN/2007-22/Jan/2008 Naryx Pharma, Inc: SPRC-AB01-003 A Phase 2, Double-bind, Placebo-Controlled, Multi-Center, Randomized Study Evaluating the Safety and efficacy of SPRC-AB01, XXXXX Solution for Nasal Inhalation, in Post-Surgical Subjects with Chronic Sinusitis
28/Jan/2010-03/OCT/2010 Alcon: C-09-033 Safety and efficacy Evaluation of topical XXXXXX in the treatment of Acute Otis Media with Otorrhea in Tympanostomy tubes
28/Jan/2010-03/OCT/2010 Alcon: C-09-041 Natural History Study of Otorrhea Following Tympanostomy tube Insertion in a Cohort of Children Aged 6 months to 12 years
22/APR/2011-01/AUG/2012 Schering-Plough Research Insititue: P08067 A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Safety of Grass (Phleum pretense) Sublingual Tablet 9SCH 697243) in Subjects Between 5 and 65 years of Age, With a History of Grass Pollen-Induced Rhinoconjunctivitis, With or Without Asthma
01/Dec/2012 – 15/JUN/2013 Otonomy: OTO-201-201101 A Prospective, Randomized, Double-Blind, Placebo-and Sham-Controlled, Multicenter, Phase 1B Study of OTO-201 Given as a Single Intratympanic Injection for Intra-Operative Treatment of Middle Ear Effusion in Pediatric Subjects Requiring Tympanostomy Tube Placement
09/NOV/2012 – 20/AUG/2014 Salvat: CIFLOTIII/10IA02 A Multicenter, Randomized, Double-Blind Clinical Trial to Assess the Efficacy and Safety of Ciprofloxacin 0.3% plus Flucinolone Acetonide 0.025% Otic Solution Compared to Ciprofloxacin 0.3% Otic Solution and to Flucinolone Acetonide 0.025% Otic Solution in the Treatment of Acute Otitis Medica with Typanostomy Tubes (AOMT) in Pediatric Patients
12/JUL/2011 – 22/DEC/2014 Optinose: A 16-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 100, 200, and 400 µg of Fluticasone Proprionate Twice a Day (BID) Using a Novel Bi-Directional Device in Subjects with Bilateral Nasal Polyposis Followed by an 8-Week Open-Label Extension Phase to Assess Safety
04/FEB/2013 – Pres. Merck P05607/001 A One-Year Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet (SCH 900237/MK 8237) in Children and Adult Subjects With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma
29/NOV/2013 – 14/JUL/2014 – Otonomy 201-201302 A Prospective, Randomized, Double-Blind, Sham-Controlled, Multicenter, Phase 3 Study of OTO-201 Given As a Single Intratympanic Injection for Intra-Operative Treatment of Middle Ear Effusion in Pediatric Subjects Requiring Tympanostomy Tube Placement
09/JAN/2014 – Pres. Otonomy 104-201102 A Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2b Study of OTO-104 Given As a Single Intratympanic Membrane Injection in Subjects With Unilateral Meniere’s Disease
30/JUN/2014 – Pres. Exela EXL CDOS-300 AOE A Phase 3, Randomized, Double-Blind, Active-Controlled, Parallel-Group Study of the Comparative Efficacy and Safety of EXL CDOS in Subjects with Acute Otitis Externa
19/MAY/2015- Pres. Autifony Clarity-1 AUT022063 A Balanced, Randomized, Placebo-Controlled, Double-Blind Study of the Efficacy and Safety of AUT00063 Versus Placebo in Age-Related Hearing Loss